Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new?

 

Launch of accredited Type 1 Childhood Diabetes CME

A new EACCME-accredited CME activity Individual Patient Management in Type 1 Childhood Diabetes has launched on epgonline.org. Intended for medical professionals involved in the management of young patients with type 1 diabetes, this module consists of six sessions, each covering a different aspect of managing psychosocial issues in type 1 childhood diabetes.

Explore at your own pace and test your knowledge using the interactive learning exercises. The activity is totally free, and on completion you will be awarded 1 European CME credit (ECMEC). 

 

Anti-Infectives Knowledge Network (AIKN) CDI Updates

Recently updated with new reports and policy updates as well as key perspectives on Clostridium difficile infection (CDI), the Anti-Infectives Knowledge Network shares expertise and experience in the area of anti-infectives.

This educational resource is an initiative by Astellas Pharma EMEA. Please remember to return often to read the news, clinical insights, and essential information from the latest anti-infective congresses.

January 2015 FDX/15/0003/EU

 

Bedwetting CME

This free CME activity covers the best practice management of nocturnal enuresis through three case study-led modules, including a more severe and complex patient scenario. It is intended for Urologists, Paediatricians, Primary Care Providers and General Practitioners looking to improve their understanding and management of bedwetting.

 

Accredited Obesity CME

The EACCME accredited European Obesity Initiative eCME module – Understanding Obesity, is freely accessible to healthcare professionals. Upon successful completion, participants will be awarded 2 European CME credits (ECMECs) and have a broad understanding of the epidemiology, contributory factors and management options for patients with obesity.

 

Type 2 Diabetes accredited CME

‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ is EACCME accredited and awarded 1 European CME credit (ECMEC). There are 3 modules:

  • A Review of Newer Therapies for Type 2 Diabetes in Combination with Insulin; John Wilding (Chair)
  • Identifying and Managing the Psychosocial Aspects of Type 2 Diabetes Mellitus; Richard Holt (Faculty)
  • Potential Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin: Interactive Case Discussion; Bernard Charbonnel (Faculty)
     

Latest News

Interim analysis of LIGHT study of Contrave (naltrexone HCl/bupropion) in CV Risk with obese patients- Orexigen/Takeda

05-Mar-2015

The LIGHT Study which the FDA had asked Orexigen not to disclose ( but whose results were disclosed with a new patent application) enrolled approximately 8900 patients who were treated with Contrave (naltrexone HCl/bupropion) or placebo. LIGHT study ...

FDA issues warning of CV Risk with testosterone products

05-Mar-2015

The FDA cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions. The benefit and safety of these medications have not been established for the treatment of low ...

FDA approves expanded indication for Prevner 13 to prevent pneumonia in adults-Pfizer

05-Mar-2015

Pfizer Inc. announced that the European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the prevention of pneumonia caused by the 13 pneumococcal ...

FDA accepts filing of Uptravi (selexipag)for treatment of PAH- Actelion

05-Mar-2015

Actelion Ltd announced the formal acceptance of the New Drug Application (NDA) for selexipag (Uptravi) by the FDA. The NDA dossier for selexipag (Uptravi) in the treatment of pulmonary arterial hypertension (PAH) was submitted to the FDA on the ...

Baxter acquires SuppreMol GmbH and with it SM 101

05-Mar-2015

Baxter International Inc and SuppreMol GmbH announced that Baxter has acquired SuppreMol for EUR 200 million (approximately $225M USD ) before working capital and other adjustments. SuppreMol is a privately held biopharmaceutical company based in ...

NICE recommends Harvoni (ledipasvir + sofosbuvir) for treatment of hepatitis C genotypes 1 and 4- Gilead

04-Mar-2015

The National Institute for Health and Care Excellence in draft guidelines recommends Harvoni (ledipasvir + sofosbuvir) for patients with genotype 1 and genotype 4 hepatitis C. Harvoni is a once a day, oral, drug which offers interferon and ribavirin ...

EU expands approval of Prevenar 13 for Pneumonia in adults-Pfizer

04-Mar-2015

The European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), from Pfizer, for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the ...

Recent Updates

Drugs

Clinical Guidelines

Guidelines on Prostate Cancer

Early and locally advanced breast cancer: Diagnosis and treatment

Medical Journals

How growth due to infant nutrition influences obesity and later disease risk

A comparison of obesity related adipokine concentrations in knee and shoulder osteoarthritis patients

The implications of obesity on pregnancy outcome

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

epgonline.org Social